Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Documenti analoghi

• Aromatase Inhibitors and Dementia Risk: Putting Safety Into Perspective
  di: Mariam Rizk, et al.
  Pubblicazione: (2025)
• Response to “Aromatase Inhibitors and Dementia Risk: Putting Safety Into Perspective”
  di: María Teresa Yuste, et al.
  Pubblicazione: (2025)
• Structure‐Guided Identification of Novel Aromatase Inhibitors Targeting Breast Carcinoma
  di: Priyanka Yadav, et al.
  Pubblicazione: (2024)
• Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor
  di: Nilesh Kapoor, et al.
  Pubblicazione: (2026)
• Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor‐Associated Musculoskeletal Symptoms in Breast Cancer
  di: Nicole M. G. Fleege, et al.
  Pubblicazione: (2025)